Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer

Figure 5

Distribution of the studied patient cohort within current classifications and the power of Cx26 and Cx46 expression to discriminate good and poor prognostic groups within the equivocal categories of NSABP, Miller-Payne G, Sataloff T, EWGBSP TR and MDAAC CPS-EG systems that are used for assessing response to neoadjuvant chemotherapy (A). Both high Cx46 levels and low Cx26 levels correlate with good prognosis (B).

Back to article page